Beyond Air, Inc. (NASDAQ:XAIR – Free Report) – Research analysts at Roth Capital lifted their FY2025 earnings estimates for shares of Beyond Air in a note issued to investors on Tuesday, February 11th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of ($0.85) per share for the year, up from their prior estimate of ($1.01). The consensus estimate for Beyond Air’s current full-year earnings is ($0.87) per share. Roth Capital also issued estimates for Beyond Air’s Q4 2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.22) EPS and FY2028 earnings at ($0.02) EPS.
Beyond Air Price Performance
XAIR opened at $0.39 on Friday. The company has a fifty day moving average price of $0.41 and a two-hundred day moving average price of $0.43. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.38 and a current ratio of 5.76. Beyond Air has a 52 week low of $0.30 and a 52 week high of $2.12. The firm has a market capitalization of $29.58 million, a PE ratio of -0.28 and a beta of -0.15.
Hedge Funds Weigh In On Beyond Air
A number of hedge funds and other institutional investors have recently made changes to their positions in XAIR. Baldwin Wealth Partners LLC MA boosted its position in shares of Beyond Air by 721.3% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 308,000 shares of the company’s stock worth $110,000 after purchasing an additional 270,500 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Beyond Air by 81.0% during the fourth quarter. Geode Capital Management LLC now owns 562,713 shares of the company’s stock worth $202,000 after purchasing an additional 251,823 shares in the last quarter. Finally, Soros Fund Management LLC bought a new position in shares of Beyond Air during the third quarter worth $573,000. 31.50% of the stock is owned by institutional investors.
About Beyond Air
Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.
Featured Articles
- Five stocks we like better than Beyond Air
- The Significance of Brokerage Rankings in Stock Selection
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- How to Invest in Insurance Companies: A Guide
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- ESG Stocks, What Investors Should Know
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.